HRT Financial LP filed a Form 3 initial statement of beneficial ownership with the SEC on November 19, 2026, disclosing that it became a greater-than-10% owner of bioAffinity Technologies, Inc. (NASDAQ:BIAF) on September 22, 2026.
Key Highlights
- Triggering event: HRT Financial LP became the beneficial owner of more than 10% of bioAffinity Technologies' outstanding Common Stock on September 22, 2026.
- Common Stock held: 116,782 shares of Common Stock held directly by the reporting person.
- Warrants held: 1,183 warrants exercisable for Common Stock, with each warrant exercisable for 1/450 of a share, held directly.
- Warrant exercise price: $3,645 per whole share, as adjusted for the issuer's reverse stock splits, with an expiration date of June 22, 2027.
- Filing relationship: HRT Financial LP is identified as a 10% owner; no director or officer relationship is indicated.
HRT Financial LP Crosses 10% Ownership Threshold at bioAffinity Technologies
According to the filing, HRT Financial LP, headquartered at 3 World Trade Center, 175 Greenwich Street, 76th Floor, New York, New York 10007, submitted its initial statement of beneficial ownership after crossing the 10% beneficial ownership threshold in bioAffinity Technologies, Inc. The date of the event requiring the statement is listed as September 22, 2026, and the form was signed by Adam Nunes and filed on November 19, 2026.
The filing discloses that HRT Financial LP directly holds 116,782 shares of Common Stock. According to footnote 1, "The reporting person became the beneficial owner of more than 10% of the outstanding Common Stock on September 22, 2026. The amount reported represents shares of Common Stock directly held by the reporting person immediately following the transaction that resulted in such status."
In addition to common shares, the filing reports 1,183 warrants (rights to buy) held directly, with an exercise date of June 22, 2022, and an expiration date of June 22, 2027. Each warrant is exercisable for 1/450 of a share of Common Stock, and the exercise price is listed as $3,645 per whole share. The filing notes this price has been adjusted for the issuer's reverse stock splits, and the underlying share amount of 2.6289 shares is rounded to four decimal places. No derivative securities are held indirectly, and no amendment to a prior filing is indicated.
What Was Disclosed
HRT Financial LP filed an initial beneficial ownership statement reporting direct holdings of 116,782 shares of Common Stock and 1,183 warrants in bioAffinity Technologies, Inc., following the firm crossing the 10% ownership threshold on September 22, 2026.




Please wait processing your request...